Effects of sibutramine treatment in obese adolescents: a randomized trial.
BACKGROUND
Increased prevalence of adolescent obesity requires effective treatment options beyond behavior therapy.


OBJECTIVE
To see whether sibutramine reduced weight more than placebo in obese adolescents who were receiving a behavior therapy program.


METHODS
12-month, 3:1 randomized, double-blind trial conducted from July 2000 to February 2002.


METHODS
33 U.S. outpatient clinics.


METHODS
498 participants 12 to 16 years of age with a body mass index (BMI) that was at least 2 units more than the U.S. weighted mean of the 95th percentile based on age and sex, to the upper limit of 44 kg/m2.


METHODS
Site-specific behavior therapy plus 10 mg of sibutramine or placebo. Blinded study medication dose was uptitrated to 15 mg or placebo at month 6 if initial BMI was not reduced by 10%.


METHODS
Body mass index, waist circumference, body weight, fasting lipid and glycemic variables, safety, and tolerability.


RESULTS
Seventy-six percent of patients in the sibutramine group and 62% of patients in the placebo group completed the study. The estimated mean treatment group difference at month 12 (linear mixed-effects model) favored sibutramine for change from baseline in BMI (-2.9 kg/m2 [95% CI, -3.5 to -2.2 kg/m2]) and body weight (-8.4 kg [CI, -9.7 to -7.2 kg]) (P < 0.001 for both). The sibutramine group had greater improvements in triglyceride levels, high-density lipoprotein cholesterol levels, insulin levels, and insulin sensitivity (P < or = 0.001 for all). The rate of tachycardia was greater with sibutramine vs. placebo (12.5% vs. 6.2%; difference, 6.3 percentage points [CI, 1.0 to 11.7 percentage points]) but did not lead to increased withdrawal (2.4% vs. 1.5%; difference, 0.9 percentage point [CI, -1.7 to 3.5 percentage points]).


CONCLUSIONS
The 1-year study duration precluded assessment of long-term weight maintenance and putative health benefits and harms, and 24% and 38% of the sibutramine and placebo groups, respectively, did not complete follow-up.


CONCLUSIONS
Sibutramine added to a behavior therapy program reduced BMI and body weight more than placebo and improved the profile of several metabolic risk factors in obese adolescents.
Berkowitz
Robert I
RI
The Behavioral Health Center, The Children's Hospital of Philadelphia and the University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA. berkowitz@email.chop.edu
Fujioka
Ken
K
Daniels
Stephen R
SR
Hoppin
Alison G
AG
Owen
Stanford
S
Perry
Arlette C
AC
Sothern
Melinda S
MS
Renz
Cheryl L
CL
Pirner
Mark A
MA
Walch
Julia K
JK
Jasinsky
Olga
O
Hewkin
Ann C
AC
Blakesley
Vicky A
VA
D000293:Adolescent; D001067:Appetite Depressants / Q000009:adverse effects / Q000627:therapeutic use*; D001521:Behavior Therapy; D001794:Blood Pressure; D001827:Body Height; D015992:Body Mass Index; D002648:Child; D003131:Combined Modality Therapy; D003503:Cyclobutanes / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D009765:Obesity / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D011674:Pulse; D012741:Sexual Maturation; D013610:Tachycardia / Q000139:chemically induced; D015431:Weight Loss
D001067:Appetite Depressants; D003503:Cyclobutanes; C058254:sibutramine